



Cancer  
Centres



# DEBATES IN URO ONCOLOGY

*Demystifying the  
Controversies*



## ORGANISING COMMITTEE

Organising Chairman : Dr. P. Vijay Anand Reddy  
Organising Secretary : Dr. Shilpa Reddy Keesara  
Dr. Sanjai Addla

For Registration  
SCAN HERE



**Apollo Medical College Auditorium**  
Apollo Hospitals, Hyderabad

**25<sup>th</sup> & 26<sup>th</sup> November 2023**

## DAY 1 – 25<sup>th</sup> November 2023

09:40 AM – 01:30 PM	<b>Session 1: Theme: How to Investigate?</b>
09:15 AM – 09:40 AM	<b>Registration</b>
09:40 AM – 09:45AM	<b>Introduction</b> Dr. Sanjai Addla, Hyderabad
09:45 AM – 11:15 AM	<b>Moderator:</b> Dr. N Ragavan, Chennai <b>CHAIRPERSONS</b> Dr. Dr. PVLN Murthy Dr. SVSS Prasad Dr. DVSLN Sharma <b>PANELISTS</b> Dr. Ravi Verma Dr. Kalyani Reddy Dr. Ravikanti Satya Prasad
09:45 AM – 10:15 AM	<b>Prostate Biopsy: Transperineal Fusion Biopsies Vs Transrectal Standard Biopsies</b>
	<b>Standard Transrectal:</b> Dr. Rajesh Adapala
	<b>Transperineal Fusion:</b> Dr. Sri Harsha
10:15 AM – 10:45 AM	<b>Stratification of MSCPC: Conventional Imaging Vs PSMA PET</b>
	<b>Conventional Imaging:</b> Dr. Anjani Prasad(NC)
	<b>PSMA:</b> Dr. Kavitha Nallapa Reddy
10:45 AM – 11:15 AM	<b>Staging of MIBC: PET CT Vs Standard Imaging</b>
	<b>PET CT:</b> Dr. Sunitha
	<b>Standard Imaging:</b> Dr. Varsha Joshi (TBC)
11:15AM – 11:45 AM	<b>INAUGURAL FUNCTION</b> <b>Welcome Address:</b> Dr. Vijay Anand Reddy <b>Objective setting:</b> Dr. Sanjai Addla <b>Address by Guest of Honour:</b> Dr.Raja Gopal <b>Lightening of Lamp:</b> <b>Address by the Chief Guest:</b> Mrs Sangeeta Reddy <b>Vote of Thanks:</b> Dr. Shilpa Reddy Keesara
11:45 AM – 12:00 PM	<b>TEA BREAK</b>

12:00 PM – 01:30PM	<b>Moderator:</b> Dr. Ganesh Bakshi <b>CHAIRPERSONS</b> Dr. Ravi Kumar Dr. Swarna Latha Dr. K Subramanyam <b>PANELISTS</b> Dr. Rekha Bansal Dr. Meenakshi Swain Dr. Srinivas Chakravarthy
12:00 PM – 12:30 PM	<b>Genetic testing should be included in the initial workup of all metastatic Prostate Cancer patients Yes Vs No</b>
	<b>Yes:</b> Dr. Surya Bala Krishnan
	<b>No:</b> Dr. Srinath Bharadwaj
12:30 PM – 01:00 PM	<b>New molecular subclassification of papillary RCC: Does have significant Clinical Implication Vs it is a Theoretical Benefit</b>
	<b>Clinical Benefit:</b> Dr. Michel D. Padua
	<b>Theoretical Benefit:</b> Dr. Stalin Chowdary Bala
01:00 PM – 01:30 PM	<b>New molecular markers and subclassification of Bladder UC: Does have significant Clinical Implication Vs it is a Theoretical Benefit</b>
	<b>Clinical Benefit:</b> Dr. Aditya Kulkarni
	<b>Theoretical Benefit:</b> Dr. Venkat Sampath
01:30 PM – 02:15 PM	<b>LUNCH</b>
02:15PM – 06:00 PM	<b>Session 2: Theme: Defining SOC for India</b>
02:15 PM – 03:45 PM	<b>Moderator:</b> Dr. Vedang Murthy <b>CHAIRPERSONS</b> Dr. D Vyas Narayana Rao Dr. Ashwin Shah Dr. Mallikarjun Reddy

	<b>PANELISTS</b> Dr. Gopichand M Dr. Yugandar Sharma Dr. Monika Mallick Dr. Sudha Sinha
02:15 PM – 02:45 PM	<b>ADT for Indian patients: Agonist Vs Antagonist</b> <b>Agonist:</b> Dr. Arabind Panda <b>Antagonist:</b> Dr. Amaresh
02:45 PM – 03:15 PM	<b>Clinical scenario of 65yearold patient who had a TURP and Orchidectomy for a localized Prostate Cancer in 2015. Now presents in 2023 with rising PSA in a CRPC setting, however, bone scan showing 2 lesions in the Spine. Local RT + Systemic treatment Vs Systemic treatment</b> <b>Local RT + Systemic Treatment:</b> Dr. Bharat G <b>Systemic treatment:</b> Dr. Meherlakshmi Konatam
03:15 PM – 03:45 PM	<b>Radiotherapy for Localised High risk Ca Prostate: SBRT Vs Standard Fractionation</b> <b>SBRT:</b> Dr. Prashant Upadhyay <b>Standard Fractionation:</b> Dr. Sajal Kakkar
03:45 PM – 04:00 PM	<b>TEA BREAK</b>
04:00 PM – 05:30 PM	<b>Moderator:</b> Dr. Senthil J. Rajappa <b>CHAIRPERSONS</b> Dr. S Jayaram Reddy Dr. Sudha Sinha <b>PANELISTS</b> Dr. Stalin Chowdary Bala Dr. N Ragavan Dr. Krishnamohan MVT
04:00 PM – 04:30 PM	<b>In the treatment of NMCRPC what is the best current option (Cipla Sponsored)</b> <b>Apalutamide:</b> Dr. Sanjai Addla <b>PARP Inhibitor:</b> Dr. Venugopal A

04:30 PM – 05:00 PM	<b>In the management of metastatic RCC in India, TKI is the first line of treatment of care Yes Vs No</b>
	<b>Yes:</b> <a href="#">Dr. G Sadashivudu</a>
	<b>No:</b> <a href="#">Dr. G Srinivas Chakravarthy</a>
05:00 PM – 05:30 PM	<b>Triplet Vs Duplet in Metastatic HSPC</b>
	<b>Triplet:</b> <a href="#">Dr. G Vamshi Krishna Reddy</a>
	<b>Duplet:</b> <a href="#">Dr. Krishna Chaitanya</a>
05:30 PM 05:45 PM	<b>Redefining Treatment Outcomes with Adjuvant Immunotherapy in RCC</b> (MSD Sponsored)
07:30 PM onwards	<b>COCKTAIL &amp; CONFERENCE DINNER</b>

## DAY 2 – 26th November 2023

09:00 AM – 01:00 PM	<b>Session 3: Theme: Quantum of Benefit</b>
09:00 AM – 11:00AM	<b>Moderator:</b> <a href="#">Dr. Sajal Kakkar</a>
	<b>CHAIRPERSONS</b> <a href="#">Dr. K Rama Raju</a> <a href="#">Dr. Kausik Bhattacharya</a>
	<b>PANELISTS</b> <a href="#">Dr. Rohith Reddy</a> <a href="#">Dr. Kirti Ranjan Mohanty</a> <a href="#">Dr. M. Gopichand</a> <a href="#">Dr. Narender Kumar Thota</a>
09:00 AM – 09:30 AM	<b>Locally advanced Mo Ca Prostate: Radiotherapy plus ADT Vs Radical Prostatectomy</b>
	<b>Radiation Therapy + ADT:</b> <a href="#">Dr. P Vijay Karan Reddy</a>
	<b>Radical Prostatectomy + E PLND:</b> <a href="#">Dr. N Ragavan</a>
09:30 AM – 10:00 AM	<b>In the management of Muscle Invasive Urothelial Carcinoma TMT Vs Radical Cystectomy</b>
	<b>TMT:</b> <a href="#">Dr. Vedang Murthy</a>
	<b>Radical Cystectomy:</b> <a href="#">Dr. Rakesh Sharma</a>

10:00 AM – 10:30 AM	<b>In management of prostate cancer Proton Vs Photon</b>
	<b>Proton:</b> Dr. Srinivas Chilikuri
	<b>Photon:</b> Dr. M Suneetha
10:30 AM – 11:00 AM	<b>Metastasis directed therapy in De Novo Oligometastatic CSPC Yes Vs No</b>
	<b>Yes:</b> Dr. Sujana Priya
	<b>No:</b> Mounika Boppana
11:00 AM – 11:30 AM	<b>TEA BREAK</b>
	<b>Moderator:</b> Dr. Srinivas Chakravathy
	<b>CHAIRPERSONS</b> Dr. M A Raouf Dr. Purna Chandra Reddy
	<b>PANELISTS</b> Dr. Mounika Boppana Dr. Vedang Murthy Dr. Shikhar Kumar Dr. Ragavan N Dr. Satyesh N
11:30 AM – 12:00 PM	<b>In the current management of metastatic RCC, Cytoreductive nephrectomy should always be considered Yes Vs No</b>
	<b>Yes:</b> Dr. Ganesh Bakshi
	<b>No:</b> Dr. Rekha Bansal
12:00 PM – 12:30 PM	<b>Immunotherapy should always be considered in the management of Metastatic Urothelial Carcinoma of the Bladder (Primary / Maintenance) (ROCHE sponsored)</b>
	<b>Yes:</b> Dr. Srinath Bharadwaj
	<b>No:</b> Dr. Tushar Tatineni

12:30 PM – 01:00 PM	<b>Post Radical Cystectomy locally advanced Urothelial Carcinoma local RT Vs Adjuvant Systemic treatment ( No Neoadj given)</b>
	<b>Local RT:</b> Dr. G. Deleep Kumar
	<b>Adjuvant Systemic treatment:</b> Dr. Rakesh Pinninti
01:00 PM – 01:15 PM	<b>Learning Points and Conclusions:</b> Dr. Sanjai Addla
01:15 PM – 01:30 PM	<b>New Paradigm in the management of Advanced Urothelial Ca</b> (MSD sponsored)
01:30 PM – 01:45 PM	<b>Management of FirstLine ALKRearranged NSCLC</b> Dr. Venkata Sampath, Hyderabad (Pfizer sponsored)
01:45 PM onwards	<b>LUNCH</b>
07:00 PM onwards	<b>Cultural Event &amp; Dinner at</b> <b>HICC Novotel, Hitec City, Hyerabad</b>



Road No 72  
Opposite Bharatiya Vidyabhavan School  
Film Nagar, Hyderabad - 500 096

